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SUMMARY
In a multi-level ‘‘deconstruction’’ of omental metastases, we previously identified
a prognostic matrisome gene expression signature in high-grade serous ovarian
cancer (HGSOC) and twelve other malignancies. Here, our aimwas to understand
how six of these extracellular matrix (ECM) molecules, COL11A1, cartilage oligo-
meric matrix protein, FN1, versican, cathepsin B, and COL1A1, are upregulated in
cancer. Using biopsies, we identified significant associations between TGFbR ac-
tivity, Hedgehog (Hh) signaling, and these ECM molecules and studied the asso-
ciations in mono-, co-, and tri-culture. Activated omental fibroblasts (OFs) pro-
duced more matrix than malignant cells, directed by TGFbR and Hh signaling
cross talk.We ‘‘reconstructed’’ omental metastases in tri-cultures of HGSOC cells,
OFs, and adipocytes. This combination was sufficient to generate all six ECM pro-
teins and the matrisome expression signature. TGFbR and Hh inhibitor combina-
tions attenuated fibroblast activation and gel and ECM remodeling in these
models. The tri-culture model reproduces key features of omental metastases
and allows study of diseased-associated ECM.
INTRODUCTION
Desmoplasia and extracellular matrix (ECM) remodeling are common features of human solid tumors and
are driven by the continued presence of malignant cells. In high-grade serous ovarian cancer (HGSOC),
there is increasing evidence that stromal components play a key role in tumor growth, promoting aggres-
sive malignant cell phenotypes (Tothill et al., 2008; Yeung et al., 2018).
Previously, we reported a tumor-associated matrisome gene signature, the matrix index (MI), which pre-
dicted poor prognosis in patients with HGSOC and 12 other solid tumor types (Pearce et al., 2018). Six
of these genes, COL11A1, COMP, FN1, VCAN, CTSB, and COL1A1, were significantly upregulated with
disease and have all previously been associated with tumor progression, poor prognosis, and invasive ma-
lignant cell phenotypes in ovarian and/or other cancers (Yeung et al., 2013; Ruan et al., 2015; Englund et al.,
2016) (Waalkes et al., 2010) (Jia et al., 2016). A number of signaling pathways have been linked with some of
these molecules including activation of FAK, TGFb-SMAD2/3 signaling, PDGF/PDGFR signaling, and Wnt
and Hh/GLI signaling (Kenny et al., 2014; Cheon et al., 2014; Yeung et al., 2013; Erdogan et al., 2017; Vaz-
quez-Villa et al., 2015); however, it is uncertain if there is a common regulatory mechanism that links them.
One of the key stromal cell types, the activated fibroblast, is a major producer of tumor ECM (Laklai et al.,
2016; Bhowmick et al., 2004; Klingberg et al., 2013; Sahai et al., 2020). These resident or infiltrating cells ac-
quire a phenotype most often characterized by expression of vimentin, alpha smooth muscle actin (aSMA),
fibroblast activation protein (FAP), fibroblast-specific protein (FSP), or yes-associated protein (YAP) (Hanley
et al., 2016; Calvo et al., 2013; Shiga et al., 2015). Previously, we reported a strong positive correlation be-
tween the density of aSMA+ and FAP+ stromal cells and the degree of disease in metastatic HGSOC 9.
Signaling pathways associated with the activation of aSMA+ fibroblasts have included, most notably,
TGFb as well as Hedgehog (Hh) 18 (Tian et al., 2009; Sahai et al., 2020; Didiasova et al., 2017).
The main goal of this study was to identify cells and signaling pathways regulating production of the six
upregulated MI molecules and then build a human multi-cellular model replicating this disease process.
We first characterized biopsies from human HGSOC omental metastases and used in silico analysis of
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Figure 1. Tumor-matrix proteins are diversely produced by stromal and malignant cells
(A) Disease score vs. tissue area (log scale) for 36 stage 3–4 HGSOC patient omental samples correlated with (B) PAX8+ malignant cells stained via IHC.
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HGSOC samples to generate hypotheses. We then isolated early passage and primary cell cultures from
biopsies for validation and to build an informed novel 3D tri-culture HGSOC model. We report that TGFbR
and Hh signaling are important regulators of the six upregulatedMI molecules that are mainly produced by
aSMA+/FAP+ omental fibroblasts (OFs) and that cross talk between these two pathways supports initiation
and maintenance of this activated phenotype. Moreover, our novel human HGSOCmodel replicated some
key features found in HGSOC omental biopsies and allowed us to understand clinically relevant regulation
of diseased-associated matrisome molecules.
RESULTS
Stromal and malignant cells diversely produce disease-associated matrix molecules
We analyzed thirty-six omental biopsies with a spectrum of tissue remodeling and disease involvement, all
from patients with stage 3–4 HGSOC. Tissues were assigned a disease score based on area of tissue re-
modeled with disease-associated stroma and malignant cells (Figure 1A) as previously described (Pearce
et al., 2018). Density of PAX8+ cells, a marker of the malignant cells, correlated strongly (r = 0.874) with dis-
ease score, as expected (Figures 1B and S1A). All omenta studied were from patients with confirmed me-
tastases, but malignant cells were only visible in 26 of 36 biopsies.
Matrisome protein density was measured by immunohistochemistry (IHC) in tissue sections and quantified
with Definiens Tissue Suite software. Density of all six upregulatedMI molecules increased significantly with
disease progression (Figures 1C, 1D, and S1B). FN1 had the strongest correlation (r = 0.969) with disease
score, had the greatest average density, and was primarily located throughout the stroma but was also
found in malignant cells in 50% (13/26) of biopsies. Versican (VCAN) was largely confined to stroma with
low malignant cell positivity (3/26 biopsies). Cartilage oligomeric matrix protein (COMP) was present in
both stroma andmost malignant cells (21/26). Cathepsin B (CTSB) was present in malignant cells of all sam-
ples with additional positivity in dense aligned stromal borders. COL11A1 was most common in stroma
adjacent to malignant cells or with high cell alignment, and there was malignant cell positivity in 16 of
26 biopsies. COL1A1 had the weakest correlation with the disease score and was found heterogeneously
throughout the stroma andmalignant cells (18/26 biopsies). Figure 1D summarizes the pattern of malignant
cell positivity for the upregulated MI molecules.
To further study origin of the upregulated MI molecules, we conducted RNAscope in situ hybridization on
highly diseased tissue sections (Figure 1E). Consistent with IHC data, FN1 and COL1A1 were expressed in
stroma adjacent to malignant cells and in some malignant cells. VCAN and COMP were expressed mostly
in stromal cells with elongatedmorphology that bordered the malignant cells. Aminority of malignant cells
had VCAN expression; however, in contrast to IHC, no COMP expression was observed in malignant cells.
CTSB was expressed in all malignant cells and in stroma at some malignant cell:stromal borders. COL11A1
was expressed in stroma adjacent to malignant cells or where stromal cells appeared elongated and there
was expression in some malignant cells.
In summary, these data support and extend our previous RNAseq and proteomic results in HGSOC con-
firming positive correlations of the upregulated MI molecules with disease score and identifying spatial
location and cellular origin.
The prognostic matrisome molecules associate with TGFb and Hh signaling
Our next aim was to identify common regulatory pathways for the six MI molecules. We first integrated pro-
tein-protein interaction and signaling pathway data from public ovarian cancer databases using
PathwayLinker.org (Farkas et al., 2012). Figure 2A illustrates the interaction network of the upregulated
MI molecules along with their first neighbor interactors. There was at least one direct or indirect interaction
linking FN1, VCAN, COMP, COL1A1, and CTSB. Based on the upregulated MI molecules and their first
neighbor interactors, TGFb (Kyoto Encyclopedia of Genes and Genomes [KEGG]) signaling pathway was
Figure 1. Continued
(D) Z score heatmap (top) of matrix area for all samples and a binary heatmap (bottom) display tumor positivity (red) or negativity (c) for matrix molecules.
(E) RNAscope in situ hybridization for the six matrix molecules (brown). Spearman’s rank correlation coefficient, r.
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significantly overrepresented (p = 2.2 3 109), along with ECM (KEGG), platelet-derived growth factor
(PDGF) (Reactome), actin (KEGG), and P53 (KEGG) (Table S1).
We next interrogated the International Cancer Genome Consortium transcriptional data set of HGSOC bi-
opsies (Patch et al., 2015) looking at association between prognosis and mean expression levels of upre-
gulated MI genes. We found that high average expression of upregulated MI genes associated with signif-
icantly worse survival in HGSOC (log rank P = 5.2 3 105) (Figure 2B). Differentially expressed genes in the
high expression group included periostin, several collagens, osteonectin, and activation markers ACTA2
and FAP (Figure 2C). Gene set enrichment analysis (GSEA) highlighted over-expression of matrisome,
ECM, collagen, focal adhesion, and smooth muscle contraction pathways (Figure 2D). Of particular interest
was significant enrichment for TGFb (KEGG), WNT (KEGG), PDGF (Reactome), and Hh (KEGG) signaling
(Figure 2D and Table S2). These results suggested that at least five of the upregulated MI molecules might
be co-regulated in HGSOC and that TGFb signaling is involved.
To investigate this further, we stained tissue sections for TGFb (Figure 2E) and found a strong correlation
between positive cell density and disease score (Figure 2F), observing the strongest staining in malignant
cells. We also stained tissues for GLI1 (Figure 2E), a main downstream target of Hh signaling, which has
been previously associated with collagen-producing aSMA+ phenotypes (Sahai et al., 2020; Tian et al.,
2009) and also implicated in TGFb cross-talk-promoting fibrosis (Didiasova et al., 2017; Javelaud et al.,
2012). Tissues with a high disease score had significant GLI1 positivity in contrast to tissues with low disease
scores that had relatively little. Malignant cells in all biopsies displayed cytoplasmic GLI1, but nuclear GLI1
varied; 16 of 26 biopsies had total nuclear positivity, four of 26 were totally nuclear negative, and six of 26
were mixed (Figure 2G). GLI1+ stromal cells were identified in 22 of 26 malignant cell biopsies displaying a
mixture of cytoplasmic and nuclear positivity.
Malignant cells upregulate TGFb3 and heterogeneously express matrisome molecules
Our next aim was to build 2D and 3D in vitro human cell models to allow us to validate and extend our find-
ings. First, we investigated two HGSOC malignant cell lines for suitability in such models. G164 was estab-
lished in our lab from patients with omental metastases and kept at a low passage number. AOCS1 was also
established from a patient with HGSOC and kept at a low passage number. Both cell lines showed genetic
changes characteristic of HGSOC (Tamura et al., 2020). The original tissue biopsies for both cell lines
showed malignant cell PAX8 positivity and cell lines cultured in vitro maintained PAX8 nuclear positivity
(Figure 3A). We characterized these HGSOC cells by RNA sequencing. Unsupervised clustering using prin-
cipal component analysis (PCA) illustrated significant transcriptional differences between the two cell lines
with the first principle component accounting for more than 89% of the difference (Figure 3B). However,
within the same cell line, there was relatively little variation between monolayer and spheroid culture.
GSEA highlighted significant canonical pathway differences between the two cell lines; notably, AOCS1
had enriched Hh-GLI signaling, and G164 was enriched in transcriptional activity of SMAD2/3/4 and
signaling by TGFbR complex (Figure 3C). The differences in Hh signaling between AOCS1 and G164
were confirmed by analyzing GLI1 expression using qRT-PCR (Figure 3D) and immunoflourescence (IF) (Fig-
ure 3E). In addition, cell proliferation, which Hh is known to affect, was significantly reduced in AOCS1 with a
GLI1/2 inhibitor, GANT61 (Thompson et al., 2015), (Figures S2A–S2C) but not in G164 (Figure S2D). The use
of a TGFbR inhibitor, SB431542 (Avgustinova et al., 2016), on the G164 cell line attenuated cell contraction
of gels and also cell migration (Figures S2E and S2F), both processes associated with activated TGFbR
signaling, but did not affect viability (Figure S2G). RNA sequencing and qRT-PCR detected five of the
Figure 2. The six upregulated matrix index molecules (FN1, COL1A1, VCAN, COMP, CTSB, COL11A1) associate with TGFb and Hh signaling
(A) Interaction network diagram obtained on PathwayLinker.org for the six upregulated matrix index molecules.
(B) Kaplan-Meier survival curve with overall survival from the International Cancer Genome Consortium ovarian data set divided by high or low average gene
expression of the six matrix index molecules. The x axis is in the unit of months.
(C) Volcano plot displays comparison of gene expression between high and low groups, highlighting significant upregulation of matrix molecules and
stromal activation markers in the high group. Red dots indicate adjusted P value <0.05.
(D) Plot of normalized enrichment score (NES) obtained from GSEA highlights over-expressed pathways in the high group compared with the low group,
including TGFb and Hh signaling (false discovery rate, FDR <0.05).
(E) IHC for TGFb and GLI1 was performed on biopsies.
(F) TGFb IHC was quantified as the number of positive cells in stained tissue.
(G) Samples with malignant cells were identified for populations with GLI1 positivity, negativity, or a mixture of both in malignant cell cytoplasm and nuclei,
as well as stromal cells. Scale bars represent 200 mm.
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Figure 3. HGSOC malignant cells have heterogeneous signaling but all secrete TGFb
(A) To identify malignant cells, HGSOC tissue sections and cells expanded in vitro were stained for PAX8 via IHC or IF, respectively.
(B) RNA sequencing was performed on AOCS1 and G164 malignant cell lines (N = 2) for adherent (Adh) and spheroid (Sph) cultures, and transcriptomic
expression was analyzed using PCA.
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six upregulated MI molecules (mRNA for COMP was not present) in the cell lines, but expression was het-
erogeneous (Figures 3F and S2H). We stained biopsy sections for differentially expressedmatrix molecules
identifying malignant cell positivity for COL11A1 and VCAN in AOCS1 and FN1 in G164 (Figure 3G). IF on
in vitro monocultures displayed strong intracellular COL11A1 staining organized into fibrils in AOCS1 and
significant deposition of FN1 by G164s (Figure S2I) replicating tissue staining.
Expression of the three TGFb isoforms was analyzed in malignant cells and compared to a non-malignant
cell control, wild-type immortalized FT318 fallopian tube surface epithelial cells (Figure 3H). Malignant cells
expressed all three TGFb isoforms with little difference between adherent and spheroid cultures, but
TGFb3 was the most highly expressed relative to FT318. TGFb3 protein was also present intra-cellularly
and secreted by both cell lines, as shown in the IF and enzyme-linked immunosorbent assays (Figures 3I
and 3J). To test the influence of malignant cell-secreted TGFb on fibroblast activation, we co-cultured ma-
lignant cells with primary OFs in collagen gels. All co-culture gels had a significantly greater gel modulus
(stiffness) compared with respective fibroblast controls (Figure 3K), while malignant cells grown alone did
not alter gel modulus (Figure S2J). In co-cultures, aSMA, FAP, and eosin staining were all increased in OFs,
but expression was attenuated using the TGFBR inhibitor (Figures 3L and S2K). Interestingly, we were un-
able to detect expression of any Hh ligands in either cell line.
These results highlight heterogeneity in cell signaling and matrisome expression in HGSOC malignant
cells, but they also reveal a commonality in upregulation of TGFb, which activates OFs via TGFbR signaling.
TGFb3 stimulates activation, GLI1 expression, and diseased-matrix production in omental
fibroblasts
Having identified TGFb as a stimulator of fibroblast activation, we next looked at associations between fi-
broblasts andmalignant cells in HGSOC omental biopsies. Density of aSMA+ or FAP+ cells correlated with
density of PAX8+malignant cells (r = 0.833 and r = 0.814, respectively) (Figure 4A), and staining was highest
in stroma adjacent to malignant cells (Figure S3A). We pseudo colored and overlaid consecutive aSMA and
FAP tissue images (Figure 4B) identifying a aSMA+/FAP+ stromal phenotype located primarily at malig-
nant cell borders where the densest matrix and GLI1 staining were previously seen.
When we isolated OFs from HGSOC omental biopsies, we observed a range of activation states in culture,
which we categorized before use in experiments as either low (L-OFs) or high (H-OFs), defined by cell
morphology and level of expression of F-actin and aSMA stress fibers (Figure S3B). Regardless of initial acti-
vation state, treating OFs with TGFb3 increased ACTA2 and FAP mRNA expression on average 4-fold and
2-fold, respectively (Figure 4C), increased IF staining for both proteins (Figures 4D and S3C) as well as the
proportion of aSMA+/FAP+ cells (Figure S3D). TGFb3 treatment also promoted F-actin fiber formation and
FSP and YAP nuclear expression (Figure S3E) in L-OFs, although differences in the latter two appeared
small. In Figure 2E, we identified GLI1-positive stromal cells in HGSOC tissue. Hh activation can promote
collagen-producing myofibroblasts in some fibrotic diseases (Horn et al., 2012), and recently, aSMA+/
GLI1+ mesenchymal cells have been identified (Schneider et al., 2018). TGFb3-treated OFs had on average
a 2.5-fold increase in GLI1 expression and a 2-fold decrease in GLI3 expression, typically considered a Hh
pathway repressor (Wang et al., 2000), while SB431542 reversed this trend (Figure 4E). GLI1 IF showed weak
cytoplasmic staining in L-OFs while TGFb3-treated L-OFs had stronger cytoplasmic and positive nuclear
staining (Figure 4F).
Figure 3. Continued
(C) GSEA was performed on transcriptomic data, and normalized enrichment scores for AOCS1 (green) vs G164 (blue) are illustrated (p < 0.1).
(D–G) (D) qRT-PCR was performed for GLI1 on AOCS1 and G164; bar plot illustrates relative expression levels of GLI1 normalized to expression in normal
fallopian tube cells, FT318-WT (red line) (E) GLI1 IF, (F) RNASeq log2RPKM gene expression of matrix molecules in AOCS1 and G164 cultures (COMP not
detected), and (G) IHC of human biopsy sections from patients AOCS1 and G164 for FN1, VCAN, and COL11A1.
(H) TGFb expression via qRT-PCR for malignant cells in vitro (N = 3), normalized to FT318-WT expression and (I) TGFb3 released by AOCS andG164 cells after
48 h of culture.
(J) IF images of TGFb3.
(K and L) OFs were cultured in 3D COL1 gels alone (control) or with (co-culture) AOCS1 or G164 cells for 7–14 days with or without TGFbRINH and then (K)
compressed to determine gel modulus (D7); each point represents mean of 2–4 gels (n = 2–4) per OF donor (N = 8), p < 0.001 (two-way, paired t test) and (L)
IHC (D14) performed on fixed sections of AOCS1 co-cultures for aSMA and FAP. Scale bars (A [bottom], E, J) are 50 mm and (A [top], G, L) are 250 mm.
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Figure 4. TGFb3 stimulates aSMA, FAP, and GLI1 expression and tumor-matrix production in omental fibroblasts
(A) IHC identified FAP or aSMA-positive cells; both correlated positively with PAX8+ cell density.
(B) IHC images of FAP and aSMA were pseudo colored and overlaid using ImageJ to highlight double-positive cells (yellow).
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Next, we analyzed expression of upregulated MI molecules in L-OFs and found that TGFb3 upregulated
mRNA expression of FN1, VCAN, COL1A1, COL11A1, and COMP (Figure 4G) and promoted matrix depo-
sition and organization (Figure 4H). Initially, there was little VCAN or COMP in confluent untreated L-OFs
but TGFb3 induced widespread deposition of both proteins. Treated cells contained denser FN1, COL1A1,
and COL11A1 fibers with greater alignment. Of particular note, COL11A1 was organized into intracellular
fibers similar in appearance to microtubules.
Tissue stiffening and contraction occurs during remodeling in fibrosis-associated diseases and is caused
largely by myofibroblasts (Desmouliere et al., 2005; Avgustinova et al., 2016). When we cultured L-OFs in
3D collagen gels for 7 days, TGFb3 treatment caused  4-fold increase in gel modulus compared with un-
treated gels (Figure 4I). Gels seeded with H-OFs formed stiffer gels than L-OFs, but modulus was signifi-
cantly reduced when treated with SB431542 (Figure S3F). Cells in TGFb3-treated gels had denser aSMA,
FAP, FN1, and COL11A1 staining compared with controls (Figure 4J).
Collectively, these experiments showed that TGFb3 promotes a aSMA+/FAP+ contractile OF phenotype
associated with an upregulation of GLI1 and increased deposition of five of the six upregulated MI
molecules.
TGFbR and GLI1/2 inhibitors downregulate aSMA, GLI1, and matrix molecules in OFs
We next asked if GLI1 played a downstream role in TGFbR pathway activation in H-OFs (Figure 5) and
TGFb3-activated L-OFs (Figure S4). Inhibitors of TGFBRI, SB431542 (Thompson et al., 2015) or Gli1/2,
GANT61 (Avgustinova et al., 2016), both reduced aSMA stress fibers in H-OFs and induced a morphology
shift from a relatively large spread cell to a smaller fusiform cell (Figure 5A). Both inhibitors reduced ACTA2
expression between 4 and 5 fold, but there was less effect on FAP (Figures 5B and S4A). Combination treat-
ment of the inhibitors caused a synergistic effect on ACTA2 resulting in >10-fold downregulation. Both in-
hibitors decreased the proportion of aSMA+/FAP+ cells with the greatest effect induced by the inhibitor
combination (Figures 5C and S4B). IF confirmed aSMA stress fibers decreased with inhibitor combination,
while again there was less effect on FAP (Figure 5D). Both inhibitors downregulated GLI1 3–5 fold and up-
regulated GLI3 2–3 fold (Figures 5E and S4C), while IF showed reduced cytoplasmic and nuclear GLI1 in H-
OFs treated with the inhibitor combination (Figure 5F).
SB431542 reduced FN1, VCAN, COL1A1, COMP, and COLL11A1 mRNA while GANT61 reduced
COL1A1, COMP, and COL11A1 (Figures 5G and S4D), implying that FN1 and VCAN are not regulated
by Hh. Overall, the inhibitor combination was most effective at downregulating collagen matrix mRNA
than each individual inhibitor. Figure 5H shows representative IF in 2D H-OF cultures for the five mole-
cules downregulated at mRNA-level molecules, confirming that the effect of the inhibitor combination is
replicated at the protein level. There was almost complete absence of VCAN and COMP; fibers of FN1
and COL1A1 were less and disrupted; and COL11A1 had lost fibrous structure. When H-OFs were grown
in 3D collagen gels, the inhibitor combination reduced density of aSMA, FAP, FN1, and COL11A1 (Fig-
ure 5I). In contrast to OFs, there was relatively little inhibitor effect on matrix expression or organization
in AOCS1 malignant cells (Figures S5A and S5B). However, in G164 malignant cells, there was a signif-
icant effect of the TGFbR inhibitor on FN1 mRNA and protein (Figures S5C and S5D), following the trend
seen in OFs, and this translated to 3D cultures whereby spheroid growth was also reduced (Figure S5E).
In addition, we observed a marked reduction in TGFb2 and TGFb3 expression in AOCS1 with Hh inhibitor
GANT61 and a 10-fold reduction in TGFb2 expression in G164 with TGFBR inhibitor SB431542 (Figures
S5F and S5G).
Figure 4. Continued
(C and D) (C) TGFb3 treatment of L-OFs caused upregulation in ACTA2 and FAP mRNA, measured by qRT-PCR, across five donors (n = 3, N = 5) and (D)
increased aSMA and FAP IF.
(E) GLI1 mRNA expression was upregulated in TGFb3-treated L-OFs (5 donors) and downregulated with SB431542 (TGFbRINH) (4 donors).
(F) IF GLI1 staining shows representative images of TGFb3-treated and untreated L-OFs.
(G) Five of the six matrix molecules were upregulated in TGFb3-treated L-OFs at mRNA level.
(H) Representative IF staining for the five upregulated molecules.
(I and J) L-OFs were cultured in COL1 gels for seven days; TGFb3 treatment increased (I) gel modulus (n = 2–3, N = 3, two-way t test, p < 0.001) and (J)
expression of aSMA, FAP, FN1, and COL11A1 visualized via IHC.
Scale bars are (B) 200 mm and (D, F, and H) 50 mm and (I) 500 mm. Blue and red lines represent control (no TGFb3 or no TGFbRINH, respectively) expression.
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We next co-cultured malignant cells with OFs in 3D gels andmeasured inhibitor effect on gel modulus. Co-
cultures treated with inhibitor alone had decreased modulus, and, overall, the combination was the most
effective (Figure 5J), also reducing the size of cell clusters in the gels (Figure 5K). Viability of co-cultures was
unaffected by inhibitors (Figure S5H).
In summary, we found that TGFb stimulates GLI1 promoting a aSMA COL1A1/COL11A1/COMP-rich ma-
trix; however, Hh signaling appeared to have little involvement with VCAN or FN1 production. We also
observed a synergy with TGFbR andGLI1 inhibition resulting in the inhibitor combination beingmost effec-
tive in attenuating activation, contraction, and matrix production. There were also regulatory differences in
the two pathways between malignant cells and OFs.
A novel 3D tri-culture replicates some key features found in HGSOC biopsies
In order to conduct pre-clinical studies of therapies that could target the poor prognostic MI molecules,
we require human 3D models that recreate more of the complexity and interactions in the tumor micro-
environment. Adipocytes are the major cell type in the normal omentum and act as a source of energy for
developing metastases (Nieman et al., 2011). We hypothesized that adipocytes could provide a relevant
biological substrate for long-term malignant cell and fibroblast co-culture allowing for the study of ma-
trisome molecule regulation and also that such tri-cultures would more closely resemble the omental tu-
mor microenvironment.
We isolated mature adipocytes from omental digests (Figure 6A) and confirmed there were viable uniloc-
ular cells. We seeded adipocytes into low-weight (0.1w%) COL1 gels in 96-well plates, enabling adipocytes
to rise up forming a compact mm-sized layer (Figure 6B). Figure 6C shows hematoxylin and eosin (H&E)
images of an adipocyte gel after 14 days of culture compared to the normal human omentum. We assessed
viability and perilipin-1, a marker of mature adipocytes, over 21 days. Although there appeared to be some
decline in viability/live stain, there was very little dead staining at day 21 (Figure 6D), and perilipin-A levels
remained relatively constant (Figure 6E). IHC for MI molecules revealed low levels of MI molecules in the
adipocyte cultures (Figure S6A).
To establish tri-cultures, we inserted seven-day co-cultures (providing time for gel remodeling) directly into
themiddle of adipocyte gels and then incubated for a further 14 days in free-swelling conditions (Figure 6F).
This time period was sufficient for remodeling of the adipose tissue and generation of cell markers and all
upregulated MI molecules (Figures 6G, 6H, and S6B). PAX8 staining identified malignant cells, while FAP
and aSMA staining identified activated fibroblasts located mainly at borders between malignant cells
and remodeled adipose tissue (Figure 6H) as we had observed in biopsies. Both malignant cells and stro-
mal cells were proliferating at 21 days as demonstrated by Ki67 staining (Figure 6H). Malignant cells were
positive for TGFb, and GLI1 positivity was present in malignant and stromal cells. All six upregulated MI
molecules were found in the stroma and some in malignant cells (Figure 6H). We conclude that tri-cultures
support malignant cell and fibroblast growth and replicate some of the key features that we have found in
patient biopsies.
To further confirm that the tri-cultures were a valid model to study regulation of MI molecules and that the
addition of adipocytes better replicated the human omental tumour microenvironment (TME), we conduct-
ed RNAseq analysis of the adipocyte gels, G164-OF collagen gel co-cultures, and theG164 tri-cultures (Fig-
ure 7A–7D). The tri-cultures had the most complex matrisome gene transcription signature (Figure 7A) and
Figure 5. TGFbR and GLI1/2 inhibitors downregulate aSMA, GLI1, and tumor matrix in OFs
(A) IF for aSMA and F-actin in L-OFs treated with TGFb3 G TGFbRInh (SB431542) or G GLI1/2 (GANT61) inhibitors.
(B-K) OFs with high activation (H-OFs) were treated with TGFbRInh or GLI1/2Inh or combination; (B) gene expression was measured by qRT-PCR for ACTA2
and FAP (N = 4 donors). (C) Cells were analyzed via flow cytometry for percentage of cells aSMA+ and/or FAP+. (D) Activated OFs were visualized via IF for
aSMA and FAP G inhibitor combination. (E) GLI1/2/3 mRNA expression analyzed via qRT-PCR for OFs and (F) GLI1 visualized via IF in activated OFs or with
combination. (G) mRNA expression of matrix molecules were analyzed via qRT-PCR for treated or untreated OFs (n = 4 donors). (H) IF visualized FN1, VCAN,
COL11A1, COMP and COL1A1, and aSMA in activated OFs with or without combination. (I) IHC of control and combination-treated OF gels for aSMA, FAP,
COL11A1, and FN1.
(J–K) OF-only gels or AOCS1 co-cultures were grown for 7 days with or without inhibitors and (J) gel modulus was measured (mean of 3 gels per donor, N = 2)
and (K) fixed sections stained for H&E.
Scale bars (A, D, F, and H) are 50 mm and (I and K) are 500. Red lines represent control (no TGFbRINH) expression.
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Figure 6. Omental adipocytes provide a physiological substrate for an HGSOC tri-culture model
(A) Fatty layer on top of the omental digest supernatant contains viable adipocytes, assessed by IF LIVE/DEAD assay.
(B) Adipocytes are mixed with collagen gel solution (0.1w%), seeded into 96-well plates, left 5 min at RT allowing cells to float upwards, before incubating at
37OC for 45min, after which gels can be carefully handled (gels transferred to 24-well plates).
(C) H&E gel sections have similar appearance to the normal omentum.
(D and E) Adipocyte gels tested for viability via IF LIVE/DEAD assay and sectioned and stained via IHC for perilipin-1 (days 0, 7, 14, and 21); data are (D) mean
of 3–5 images per donor (N = 3) and (E) median with interquartile range (N = 5).
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showed a significant enhancement of ECM, adhesion, collagen fibril organization, and also cell migration
signatures compared to the G164-OF co-cultures (Figure 7B and Table S3). Twenty-one of the 22 MI mol-
ecules originally identified by us in HGSOC omental metastases (Pearce et al., 2018) could be sufficiently
detected by RNAseq, allowing us to calculate the MI of adipocyte-only gels, G164-OF cultures, and tri-cul-
tures. Tri-cultures had an increased MI compared with adipocyte-only gels and co-cultures (Figure 7C) with
values similar to diseased omental metastases from patients with HGSOC (Pearce et al., 2018). The cluster
dendrogram also shows a clear separation between adipocyte cultures, co-cultures, and tri-cultures
(Figure 7D).
TGFbRI and GLI1/2 inhibitor combination reduces matrisome production in tri-cultures
Having shown that MI levels were comparable to the biopsies and implicating TGFbR and Hh signaling in
regulation of the upregulated MI molecules, we tested their inhibitors in the tri-cultures. We used the in-
hibitor combination as we saw previously that it was most effective at reducing OF activation and matri-
some molecules. The inhibitor combination did not affect total cell viability (Figure S7A) but significantly
reduced adipocyte gel contraction in all tri-cultures (Figures 7E and S7B) and reduced remodeling or ma-
lignant cell invasion of adipocytes (Figure S7C). Confocal microscopy showed a noticeable reduction in all
six upregulated MI molecules imaged in tri-cultures treated with the inhibitor combination (Figures 7F and
S7D). In controls, G164 cells formed large colonies surrounded by activated fibroblasts, but with the inhib-
itor combination, malignant colonies were significantly smaller and widely dispersed. In treated AOCS1 tri-
cultures, matrix molecules and activation markers were also reduced and compared with controls (Figures
7F and S7D).
We also conducted RNAseq onG164 tri-cultures with the inhibitor combination. Unsupervised clustering of
the data showed that the inhibitor-treated cultures segregated separately from the control tri-cultures (Fig-
ure S7E). Expression levels of fibroblast activation markers and the six upregulated MI molecules, including
CTSB, were significantly reduced by the inhibitor combination (Figure 7G). GSEA showed significant down-
regulation of pathways associated with matrisome, ECM, collagens, as well as TGFb and Hh signaling
(Figures S7F, S7G, and 7H and Table S4). The overall MI was reduced to the level of the adipocyte gels
or co-cultures (Figure 7I).
These experiments demonstrate that this novel tri-culture model replicates key features of the omental
HGSOC tumor microenvironment, especially matrisome components from the MI signature. Moreover,
we can use this model to investigate regulation of tumor-associated components.
DISCUSSION
We recently published a multi-level analysis of developing HGSOCmetastases (Pearce et al., 2018). One of
the significant findings was a pattern of 22 matrisome genes which we termed the MI that significantly
changed with disease progression and was highly prognostic in ovarian and twelve other solid human can-
cers. Six of these molecules were significantly upregulated with disease progression and sixteen downre-
gulated. In the present work, we have shown that expression levels of the six upregulated MI molecules
themselves predict poor prognosis in HGSOC and associate with an activated aSMA+/FAP+ fibroblast
phenotype regulated by TGFbR activity and Hh signaling.
We used the knowledge gained from our previous analysis of HGSOC metastases, further studies on
HGSOC biopsies, in silico analysis, and in vitro cultures to inform and build a relevant 3D multi-cellular
model of the tumor microenvironment. We facilitated sustained production of key matrisome proteins in
tri-cultures by cell types also found in patient biopsies, and RNAseq analysis demonstrated that several
important features of the diseased biopsies, especially related to ECM regulation, cell adhesion, and
migration, as well as the MI gene expression signature, were enhanced in the tri-cultures. Interestingly,
compared to responses with monolayers on stiff plastic, FAP expression was significantly downregu-
lated, and CTSB expression was also downregulated with the inhibitor combination in tri-cultures. These
Figure 6. Continued
(F) Schematic shows constituents and cells used to assemble and grow tri-cultures.
(G and H) AOCS1 tri-cultures grown for 21 days and then fixed, sectioned, and stained for H&E and via IHC; colored squares in (G) mark location of colored
borders for IHC (H).
Scale bars (A, C, and D) are 100 mm, (E and H) are 200 mm, (G) and 500 mm.
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Figure 7. TGFbR and GLI1/2 inhibitor combination reduces tumor matrix expression in HGSOC tri-cultures
RNAseq was performed on adipocyte-only gels (Adipo_only), control tri-cultures (G164Tri), G164 + OF co-cultures, and G164Tri treated with inhibitor
combination (G164Tri + CombI).
(A) Heatmap of all matrisome genes detected in Adipo_only, G164 + OF, and G164Tri.
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differences implicate the importance of a physiologically relevant biomechanical environment, and our
results show that human 3D multi-cellular models can be useful for studying some aspects of cancer
biology.
We demonstrated that TGFb signaling plays a powerful role in induction of an aggressive fibroblast pheno-
type, which is responsible for deposition of disease-associated matrix that predicts poor prognosis. TGFb
ligands play important roles in development, homeostasis, and wound healing, and all three known iso-
forms act through the same receptor signaling pathway (Kubiczkova et al., 2012). The TGFb pathway is
widely acknowledged as essential for tumor progression and can play pivotal roles as both a promoter
and suppressor of cancer cells. Cancer cells can acquire loss-of-functionmutations and lose responsiveness
to TGFb, thereby bypassing cell cycle arrest (Zhang et al., 2018). TGFb plays an important role in recruit-
ment and activation of cells of the innate immune system but also acts to suppress immune cell functions
(Yang et al., 2010). Additionally, TGFb plays an essential role in regulation of the adaptive immune system,
and its continued presence can suppress T-cell functions and promote pro-tumorigenic phenotypes (Caja
et al., 2018; Tauriello et al., 2018).
More recently, TGFb has been recognized for its potential regulatory role in the stromal microenvironment,
which in turn plays an important role in tumor progression. In our study, we identified that malignant cell
lines expressed all three TGFb isoforms, and TGFb-2/3 ligands were upregulated compared to our non-ma-
lignant control with the greatest increase for TGFb3. TGFb3 has previously been associated with a set of
poor outcome genes in serous ovarian cancer (Cheon et al., 2014). We showed that TGFb3 induced
aSMA, FAP, and GLI1 expression in OFs and promoted production of five upregulated MI molecules. Of
particular interest is a recently published bioinformatics analysis of pan-cancer transcriptional ECM regu-
lation in cancer (Chakravarthy et al., 2018). Chakravarthy et al reported that their ECM signature was linked
to TGFb signaling and was a biomarker of failure to respond to immune checkpoint blockade (Chakravarthy
et al., 2018). Response to an anti-PDL1 agent in patients withmetastatic bladder cancer was also associated
with increased TGFb signaling in patient biopsies (Mariathasan et al., 2018) and treatment of tumor-bearing
mice with inhibitors of TGFb or its receptor enhanced response to anti-PD1/PDL-1 therapies (Tauriello
et al., 2018) (Mariathasan et al., 2018).
Further evidence for the role of TGFb in HGSOC progression comes from related 3D culture experiments.
We developed a tetra-culture, comprising layers of human adipocytes, fibroblasts, mesothelial cells, and
malignant cells, to model the role of platelets in early HGSOC metastases to the omentum (Malacrida
et al., 2021). TGFb, particularly from platelets, was again implicated in ECM deposition but also malignant
cell EMT and invasion via actions on both malignant cells and mesothelial cells.
In this paper, we have also highlighted apparent cross talk between TGFbR and Hh, as both pathways
promote aSMA in OFs such that TGFbR stimulates GLI1 signaling leading to increased aSMA expression.
FN1 and VCAN were upregulated by TGFb, in agreement with previous studies, but Hh appeared to
have little involvement. However, there was a strong indication that Hh enhances COL1A1, COL11A1,
and COMP and that the GLI1/2 inhibitor created a synergistic inhibitory effect when used with the TGFbR
inhibitor. Interestingly, the GLI1/2 inhibitor did not influence matrix molecule expression in malignant
cells, even in AOCS1, which had enriched Hh-GLI pathway activity, implying that the signaling mecha-
nisms either have a functional loss or are different between cell types. However, GLI1/2 inhibition did
Figure 7. Continued
(B) GSEA was performed on differentially expressed genes in G164Tri vs G164 + OF; bar plot indicates normalized enrichment scores (NES) for the indicated
gene ontologies (p < 0.05).
(C) Matrix index was calculated from the RNAseq data across the samples.
(D) Hierarchical cluster analysis of transcriptomes for indicated samples.
(E) After 21 days of culture, gel areas of control and combination-treated tri-cultures were measured from images (insets show 2 different experiments); data
are mean of 2–4 gels per experiment (N = 5), p < 0.05 (two-way, paired t test).
(F and G) (F) IF on tri-cultures for EPCAM, aSMA, FN1, VCAN, COL1A1, COMP, COL11A1, and DAPI (blue), scale bars represent 100 mm. G164Tri was treated
with inhibitor combination and subjected to RNAseq (G) Volcano plot used to visualize changes in expression between G164Tri treated with inhibitors
(G164Tri + CombI) and control G164Tri. Red dots indicate adjusted P value <0.05.
(H) GSEA performed on the differentially expressed genes between G164Tri + CombI and G164Tri; enrichment plot derived from GSEA of RNA sequencing
data of G164 tri-cultures.
(I) Matrix index for G164Tri and G164Tri + CombI. For RNA sequencing, 2 gels were pooled per sample, Adipo_only (n = 1), G164Tri, and G164Tri + CombI
(n = 2).Scale bars represent 100 mm.
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reduce proliferation in AOCS1. In addition, expression of Hh ligands was not detected in either HGSOC
cell line, indicating that GLI1 activation in OFs was not due to malignant cell-secreted Hh ligands. These
two separate observations of inhibition synergy and GLI1 stimulation by TGFb signaling suggest that Hh
is likely to be activated by more than one pathway, and therefore, inhibition of TGFbR activity does not
silence all Hh activity. This demonstrates potential for use of GLI inhibitors in cancers that have poor
prognostic Hh-stromal signatures and malignant cell Hh activity, and there may be added benefit
from combination treatment with TGFbR inhibitors. Currently, the most clinically advanced group of
Hh inhibitors targets smoothened (SMO) inhibitors (Pak and Segal, 2016), which is upstream of GLI1.
However, there have been cases where malignant cells developed clinical resistance to SMO inhibitors
via a number of different mechanisms (Pak and Segal, 2016) and therefore directly targeting GLI may
offer more promise in bypassing SMO-resistant cells.
All six upregulated MI molecules have previously been linked to tumor progression. In particular, COL11A1
expression is consistently linked with poor prognosis in solid metastatic carcinomas (Cheon et al., 2014; Vaz-
quez-Villa et al., 2015; Jia et al., 2016). While COL11A1 has been implicated as a specific biomarker of activated
fibroblasts (Jia et al., 2016), it canalsobeexpressed inepithelial cells with highmetastatic potential (Vazquez-Villa
et al., 2015). Indeed, in this study, we demonstrated that AOCS1was highly positive for COL11A1, and there was
malignant cell nuclear positivity in >50%of our biopsies. Interestingly, in our cells, COL11A1was intracellular and
highly expressed in cells with active Hh signaling. Use of the inhibitor combination onOFs caused a total break-
down of COL11A1 fibrous structure, in line with loss of aSMA stress fibers, suggesting a role in forming a stable
and contractile phenotype. We believe that this warrants further investigation.
In conclusion, the main drive for creating human models of the tumor microenvironment is to study pro-
cesses governing disease progression in a more physiologically relevant setting and to aid pre-clinical
testing. The multi-cellular model we describe here could be useful for screening compounds that could
modify the malignant matrisome that associates with poor prognosis in 13 common human cancers. The
most promising candidates could then be tested in mouse models that most closely replicate the human
TME, either patient-derived xenografts or models such as our recently published new syngeneic mouse
HGSOC models that replicate many features of the human omental TME (Maniati et al., 2020).
In our model, TGFbR and GLI inhibitors attenuated fibroblast activation and tumor-associated matrix
production while preventing malignant cells from forming large spheroid growths. Therefore, inhibitors
of these pathways may have clinical potential, alone or in combination. While we do not know if these
processes have the potential to increase malignant cell dissemination due to removal of the physical
matrix barrier, it is also possible that this may facilitate better access for cancer treatments or immune
cells. We believe that our novel tri-culture model will be a useful first step in pre-clinical evaluation of
therapies targeting a dysregulated matrix in human solid cancers and their effect on immune cell access
to malignant cells. Moreover, we believe that our work demonstrates the usefulness of using a combi-
nation of mono-, co-, and multi-cellular cultures to understand cell-cell interactions in the tumor
microenvironment.
Limitations of the study
While we were able to validate data obtained from analyses of human tumor biopsies in the tri-culture
model, there may be other cells and signaling pathways involved in the regulation of poor prognostic
ECM molecules in a more complex tumor microenvironment. In future studies, we aim to increase the
complexity of the models. We have already shown that it is feasible and valuable to include mesothelial
cells in our multi-cellular models (Malacrida et al., 2021) and are currently adding myeloid cells to investi-
gate further signaling pathways that regulate poor prognostic ECM molecules.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Monoclonal Mouse Anti Alpha Smooth Muscle
Actin
Sigma Cat# A2547; RRID:AB_476701
Monoclonal Mouse Anti Actin Sigma Cat# A1978; RRID:AB_476692
Polyclonal Rabbit Anti Versican Sigma Cat# HPA004726; RRID:AB_1080561
Polyclonal Rabbit Anti COL11A1 Sigma Cat# HPA052246; RRID: N/A
Polyclonal Rabbit Anti COL1A1 Sigma Cat# HPA011795; RRID:AB_1847088
Polyclonal Rabbit Anti FN1 Sigma Cat# F3648; RRID:AB_476976
Monoclonal Mouse Anti Ki67 Dako Cat# M7240; RRID:AB_2142367
Monoclonal Rabbit anti-fibroblast activation
protein, alpha
Abcam Cat# ab207178; RRID:AB_2864720
Monoclonal Rat anti COMP Abcam Cat# ab11056; RRID:AB_297708
Monoclona Mouse anti CTSB Abcam Cat# ab58802; RRID:AB_940824
Polyclonal Rabbit anti PAX8 Novus Cat# NBP1-32440; RRID:AB_2283498
Human anti EpCAM Alexa Flour 488 Thermo Fisher Cat# 53-8326-41; RRID:AB_11220074
Monoclonal Mouse anti GLI1 Santa Cruz Biotechnology Cat# sc-515751; RRID: N/A
Human Fibroblast Activation Protein alpha PE-
conjugated Antibody (FAP-PE) (Clone #
427819)
R&D systems Cat# FAB3715P; RRID: N/A
Human alpha-Smooth Muscle Actin APC-
conjugated Antibody (aSMA-APC) (Clone
#1A4)
R&D systems Cat# IC1420A; RRID:AB_10890600
Alexa Fluor 568 Phalloidin ThermoFisher Cat# A12380; RRID: N/A
Biotinylated goat anti-rabbit IgG antibody
1.5mg
Vector Labs Cat# BA-1000; RRID:AB_2313606
Biotinylated goat anti-rabbit IgG antibody
1.5mg
Vector Labs Cat# BA-9200; RRID:AB_2336171
Anti-TGF beta 1 antibody [2Ar2] Abcam Cat# ab64715; RRID:AB_1144265
Biological samples
Formalin Fixed Paraffin Embedded Human
Omental Blocks
Barts Cancer Institute - Gynae-oncology
Biobank
(https://directory.biobankinguk.org/Profile/
Biobank/GBR-1-128) HTA license number
12199 (REC no: 10/H0304/14 and 15/EE/0151)
Chemicals, peptides, and recombinant proteins
Trypsin-EDTA solution 10X Sigma T4174
DMEM/F12 with Glutamax Thermo Fisher Scientific 31331093
FBS Fisher Scientific 10500-064
Collagenase type I powder Thermo Fisher Scientific 17100017
Cholera Toxin from Vibrio cholerae Sigma C8052-.5MG
Recombinant Human TGFb3 Peprotech 100-36E
SB431542 hydrate Sigma S4317
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REAGENT or RESOURCE SOURCE IDENTIFIER
Collagen I from rat tail Thermo Fisher Scientific A1048301
DMEM low glucose 10x Sigma D2429
Permeabilization Buffer (10X) eBioscience 00-8333-56
Fixation/Permeabilization Diluent eBioscience 00-5223-56
Fixation/Permeabilization Concentrate eBioscience 00-5123-43
Goat serum 100ml Life Technologies 16210064
Fixable Viability Dye eFluor 450 eBioscience 65-0863-18
Agilent RNA 6000 Pico Reagents Agilent 5067-1514
Medium-199 Thermo Fisher Scientific 22350029
Fluorescein diacetate Sigma F7378-5G
Ethidium Homodimer I Solution Sigma E1903
Insulin-Transferrin-Selenium-Sodium Pyruvate
(ITS-A) (100X)
Thermo Fisher Scientific 51300044
Zytomed Antibody diluent Bioscience LifeSciences ZUC025-500
Bovine Serum Albumin Sigma A4503
Hydrogen Peroxide 30% (w/v) (100 Volumes),
Extra Pure SLR, Fisher Chemical
Fisher Scientific 10687022
Vectastain Elite ABC HRP Kit Vector Laboratories PK-6100
SIGMAFAST DAB Tablets Sigma D4293
Hematoxylin Solution, Gill No. 1 Sigma GHS116
Formalin solution neutral buffered 10% Sigma HT501128-4L
DPX Mountant for histology Sigma 06522
Triton X-100 Sigma T8787
DAPI Biotium 40043
Critical commercial assays
RNeasy Micro Kit (50) Qiagen 74004
TGFb3 ELISA kit Abcam 272203
High-Capacity cDNA Reverse Transcription Kit
(200 reactions)
Thermo Fisher Scientific 4368814
iTaq Universal Probes Supermix (10 x 1ml) Biorad 1725132
Deposited data
RNASeq on HGSOC cell-line mono-cultures
and tri-cultures
GEO GSE125109
Experimental models: Cell lines
Human AOCS1 Kindly gifted by Prof D Bowtell’s lab Tamura et al., 2020. https://doi.org/10.1158/
0008-5472.CAN-19-0852. Epub 2020 Sep 30.
PMID: 32998996.
Human G164 isolated in our lab Tamura et al., 2020. https://doi.org/10.1158/
0008-5472.CAN-19-0852. Epub 2020 Sep 30.
PMID: 32998996.
Oligonucleotides
See Table S5 N/A
Software and algorithms
FlowJo 9.4.6 Treestar Inc. https://www.flowjo.com/
GraphPad Prism 8.3.0 GraphPad https://www.graphpad.com/scientific-
software/prism/
(Continued on next page)
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Further information and requests for resources and data should be directed to the lead contact, Frances
Balkwill (f.balkwill@qmul.ac.uk), Barts Cancer Institute, Queen Mary University of London Charterhouse
Square EC1M 6BQ, London, UK.
Materials availability
This study did not generate new unique reagents.
Data and code availability
The accession number for the RNASeq data reported in this paper is Gene Expression Omnibus (GEO):
GSE125109.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Ovarian cancer patient samples and study approval
Patient samples were kindly donated by women with HGSOC undergoing surgery at Barts Health NHS
Trust. Tissue deemed by a pathologist to be surplus to diagnostic and therapeutic requirement were
collected together with associated clinical data under the terms of the Barts Gynae Tissue Bank (HTA
license number 12199. REC no: 10/H0304/14). The patients ages ranged from 40-87. Each patient gave writ-
ten informed consent and all tissue used for this study was approved by a UK national review board. Studies
were conducted in accordance with the Declaration of Helsinki and International Ethical Guidelines for
Biomedical Research Involving Human Subjects (CIOMS).
HGSOC cell lines
The AOCS1 cell line was established in our laboratory from an omental HGSOC tumor collected during in-
terval debulking surgery in 2011 (Milagre et al., 2015). The G164 cell line was established in our laboratory
from an omental HGSOC tumor collected during interval debulking surgery in 2015. G164 cells were TP53
and PAX8 positive (Tamura et al., 2020). Malignant cells were cultured in DMEM:F12 (Gibco), 10% FCS, 1%
penicillin and streptomycin in a 5% CO2 humidified incubator at 37C. The immortalized human FTSE cell
line, wild-type FT318, was kindly given by Professor Ronny Drapkin (Perelman School of Medicine, Univer-
sity of Pennsylvania) and grown in serum-free WIT-P medium (Cellaria) without antibiotics and 100ng/ml
cholera toxin (Sigma-Aldrich). Quality control of all cell lines was carried out by frequent STR analysis (Euro-
fins MWG), mycoplasma testing (InvivoGen) and cell lines were used for 4 to 5 passages.
METHOD DETAILS
RNA in situ hybridization
Sections (4 mm) of formalin-fixed paraffin embedded (FFPE) human omentum samples were deparaffinised,
treated with hydrogen peroxide and boiled in the target retrieval reagent. Sections were dried in ethanol
and left at room temperature (RT) overnight. Slides were incubated in protease reagent at 40oC in a HyBEZ
Hybridization System (Advanced Cell Diagnostics Inc. USA) followed by incubation at 40oC with the gene-
specific probe. The AMP 1-6 reagents were all subsequently hybridized as specified in the manufacturer’s
Continued
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R 3.1.3 NA http://www.R-project.org
Definiens Definiens Inc. N/A
HTSeq https://htseq.readthedocs.io/en/release_0.11.
1/
Anders et al., 2014
EdgeR Bioconductor Robinson and Oshlack, 2010
Limma Bioconductor Ritchie et al., 2015
GSEA https://www.genepattern.org/ Subramanian et al., 2005
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instructions. Labeled mRNAs were visualized using DAB reagent and counterstained using 50% Gill’s he-
matoxylin. Counterstained slides were dehydrated using 70% and 95% ethanol and cleared in xylene before
mounting coverslips using DPX. RNAscope probes: FN1 (Hs-FN1 310311), COL1A1 (Hs-COL1A1 401891),
VCAN (Hs-VCAN 430071), CTSB (Hs-CTSB 490251), COMP (Hs-COMP 457081), COL11A1 (Hs-COL11A1
400741), all from Advanced Cell Diagnostics.
Isolation of primary cells from human omentum
Fresh tissue was washed in phosphate buffered saline (PBS) and approximately 10cm3 of omentum was
submerged in 0.25% trypsin (Sigma-Aldrich) and incubated at 37oC for 20min to strip off any mesothelial
cells. Trypsin was neutralized using DMEM:F12 1:1 medium (Gibco) with 10% heat-inactivated fetal bovine
serum (FBS) (Hyclone). Tissue was washed with PBS, minced with dissection scissors into approximately 1-
2mm pieces, suspended in DMEM (Sigma) with 5% FBS and 0.5 mg/ml collagenase type I (Gibco) and
placed in a shaking incubator at 50rpm and 37oC for 75 min. Tissue digest was passed through 250 mM tis-
sue strainers (Thermo-Fisher) and the floating adipocyte layer was carefully collected by pipette and
washed by centrifuging twice for 5min at 200g in DMEM with 5% FBS. Adipocytes were used immediately
for experiments. The stromal vascular fraction (SVF) pellet from the first wash was resuspended in
DMEM:F12 1:1 + 10% FBS (growthmedium) and cultured at 37oC, 5%CO2. After three days, any unattached
cells were washed away and attached cells were checked for fibroblastic morphology, and henceforth
referred to as omental fibroblasts (OFs). Media was changed every 2-3 days and cells were passaged
upon reaching confluence and used for experiments between passages 2-4. Multiple fibroblast donors
were used for each experiment and data was plotted for each individual donor with no pooling. In total,
fibroblasts from 23 different donors including from tissue with little disease and tissues with confirmed
disease.
Monocultures
For mRNA extraction and flow cytometry, OFs were seeded at 200k and malignant cells were seeded at
500k in T25 flasks and grown for 4 days. For IF, OFs were seeded at 30k and malignant cells at 60k in 12-
wells and grown for 4 days for cell markers and 14 days for matrix molecules. The appropriate factors
and inhibitors were added 24h after seeding and replenished every 48h; recombinant TGFb3 10ng/ml
(Peprotech); SB431542 hydrate 20mM (Sigma-Aldrich); GANT61 7.5mM (InSolution, Merck); L-ascorbic
acid-2-phopsphate (AA2P) 50mg/ml (Sigma-Aldrich). AA2P was only added for experiments involvingmatrix
production.
Collagen gel cultures
Collagen-gel solution (0.1w%) was made for 3D mono- and co-cultures mixing (per 100ml gel) 34ml of 3mg/
ml rat-tail collagen I (Gibco), 4ml of 10x DMEM low-glucose (Sigma), 2ml of 1M NaOH and 60ml DMEM:F12
containing cells, prepared on ice. OF-only gels were seeded at 40k and grown for 7 days. Malignant cell-
only gels were seeded at 80k and grown for 14 days. Co-cultures were seeded at a ratio of 1:1 (100k:100k)
OFs to malignant cells and grown for 7 days. All gels were aliquoted at 100ml in 96-wells and incubated at
37oC, 5% CO2 for 45min to set and then transferred to free-float in 24-wells with growth medium.
Flow-cytometry
For mono-layers, fibroblasts were detached using 0.5% trypsin-EDTA, centrifuged, washed in PBS and re-
suspended in FACS buffer containing Human Fibroblast Activation Protein alpha PE-conjugated Antibody
(FAP-PE) (R&D systems FAB3715P, Clone # 427819) on ice in darkness for 30 min. After centrifugation and
washing in FACS buffer, cells were suspended in fixation/permeabilization solution (BD Biosciences) for
30 min on ice, washed in permeabilization/wash (PW) buffer, then incubated in 2% goat serum. Human
alpha-Smooth Muscle Actin APC-conjugated Antibody (aSMA-APC) (R&D systems IC1420A, Clone #1A4)
was added for 30 min before cells were washed in PW-buffer.
For gels containing cells, cultures were digested in 1mg/ml collagenase type I (Thermo-Fisher) in serum-
free DMEM for 1hr with shaking at 110 rpm and 37oC. Gels were disaggregated with pipetting and 0.5%
trypsin-EDTA (Sigma-Aldrich) was added at 37oC for 30 min. DMEM with 10% FBS was added 1:1 to the
cell suspension and centrifuged at 200g for 5min. For live-dead assay, cells were resuspended in FACS
buffer (PBS with 2mMEDTA, 2.5% BSA) containing Fixable Viability Dye eFluor 450 (FVD-e450) (eBioscience
65-0863-18) for 30 min on ice protected from light. After washes in FACS buffer, cells were fixed in neutral
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buffered formalin. Stained samples were analyzed using an LSRFortessa cell analyzer (BD Biosciences) and
data were analyzed with FlowJo 9.4.6 (Treestar Inc.).
Mechanical characterization of gels
Compression was performed using an Instron ElectroPulse E1000 (Instron, UK) equipped with a 10N load
cell (resolution = 0.1 mN). Gels were submerged in PBS throughout testing. Gels were compressed using a
stainless steel plane-ended platen with diameter > 2x gel diameter connected directly to the load cell. Gel
thickness was measured as the distance between the base of the test dish and top of the gel, each detected
by applying a pre-load of 0.3-5 mN. Tests were performed in displacement control mode and gels were
displaced to 30% thickness at a rate of 1%s-1 with the resulting load recorded. Gel modulus, a measure
of material stiffness independent of specimen geometry, was calculated by converting load-data to stress
(kPa) (loadO gel area), plotting a stress-strain curve and then taking the slope of the curve between 15-20%
strain.
RNA isolation and real-time quantitative PCR
Total RNA was extracted using Qiagen RNeasy Plus Micro kit according to the manufacturer’s instructions.
Monolayers were first scrapped in RLT Plus buffer (Qiagen) and RNA was quantified using a NanoDrop
2000c (Thermo-Fisher Scientific). Tri-cultures were placed directly into RLT buffer and rigorously vortexed.
RNA quality was analyzed on Agilent bioanalyzer 2100 using RNA PicoChips according to manufacturer’s
instructions. RNA integrity numbers were between 8.1 and 9.9. Total and reverse-transcription was carried
out on 1mg of RNA using a T100 Thermal Cycler (Bio-Rad) and a High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) according to manufacturer’s instructions. The PCR reaction was run on a StepO-
nePlus Real-Time PCR System (Applied Biosystems) using iTag Universal Probes Supermix (Applied Bio-
systems), FAM-MGB labeled Taqman gene expression probes and 5ng sample cDNA. Taqman gene
expression assay targets; ACTA2 (Hs00426835_g1), FAP (Hs00990791_m1), GLI1 (Hs00171790_m1), GLI2
(Hs01119974_m1), GLI3 (Hs00609233_m1), TGFb1 (Hs00998133_m1), TGFb2 (Hs00234244_m1), TGFb3
(Hs01086000_m1), FN1 (Hs01549976_m1), COL1A1 (Hs00164004_m1), VCAN (Hs00171642_m1), CTSB
(Hs00947433_m1), COMP (Hs00164359_m1), COL11A1 (Hs01097664_m1); GAPDH (Hs027866254_g1) and
18S (Hs03003631_g1), were both used as housekeeping genes (All from Thermo-Fisher Scientific, UK).
Preparation of adipocyte-collagen gels
Purified adipocytes (1ml) were combined with the following reagents to give 0.1w% collagen-adipocyte
gels: 1ml of 3mg/ml rat-tail collagen I, 100ml of 10x DMEM low-glucose, 48ml of 1M NaOH and 852ml
H2O, prepared on ice. Adipocyte-gel mixture was incubated at 37
oC, 5% CO2 for 45min in 100ml aliquots
in a 96-well dish. Gels were gently transferred to 24-wells and cultured in 1ml Medium-199 with insulin-
transferrin-selenium (Gibco). Adipocyte gels were used for experiments with other cell types within
7 days of isolation. For live/dead assays, gels were immersed in 1ml PBS containing 20mg fluorescein diac-
etate (Sigma-Aldrich) and 4mM ethidium homodimer (Sigma-Aldrich), incubated for 10min at 37oC, then
placed on a glass slide with PBS to prevent drying. Gels were imaged using a Zeiss LSM510 confocal
microscope.
ELISA
G164 and AOCS were grown in 24-well plates until 70% confluency. After 48h, media was collected, spun
down and tested for the presence of TGFb3 using a TGFb3 ELISA kit (Abcam 272203).
Preparation of tri-cultures
3D co-cultures of fibroblasts and HGSOC cells were first cultured for 7 days to allow gel contraction and
remodeling. Adipocyte gels were placed in dry 24-wells and then using a Pasteur pipette, a co-culture
gel with a small volume of media was placed on top of the middle of an adipocyte gel. Co-cultures were
embedded into the center of adipocyte gels by carefully pressing down with the curved end of a sterile
1.5ml eppendorf. Wells were then filled with culture media and tri-cultures were allowed to free-float. After
24 hours, ascorbic acid (50mg/ml) was added to gels without or with inhibitors, SB431542 (20mM) and
GANT61 (7.5mM). Gel images were acquired before adding factors and at the end of culture (14 days). Me-
dia and factors were replenished every 2-3 days and cultured for a further 13 days. At the end point (21 days
total culture), tri-cultures were washed well with PBS and fixed in 10% formalin for 2h for IF, or for 24h for
paraffin embedding. After fixation, gels were stored in PBS at 4oC until processed.
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FFPE sections (4 mm) of omentum samples or gel-cultures were re-hydrated in ethanol solutions: 100%,
90%, 70%, and finally 50%. Sections were transferred to citric acid-based antigen unmasking solution (Vec-
tor Laboratories) and heated in a 2100 antigen-retriever (Aptum Biologics). Sections were treated with 3%
H2O2 for 5min and blocked with 5% BSA for 1hr. Primary antibody was added in antibody diluent (Zytomed)
for 1hr. Slides were washed and a biotinylated secondary antibody (Vector) was added. Subsequent steps
were carried out according to the protocol included with the Vectastain Elite ABC HRP kit. Slides were incu-
bated for 5min with DAB solution made using Sigmafast DAB tablets (Sigma-Aldrich). Finally, slides were
counterstained in 50% Gill’s hematoxylin I, and dehydrated in 50%, 70%, and 100% ethanol then twice in
xylene. Coverslips were affixed using DPX mountant (Sigma-Aldrich). All sections were scanned using a
3DHISTECH Panoramic 250 digital slide scanner (3DHISTECH), and the resulting scans were analyzed using
Definiens software (Definiens AG). Disease scores were determined first by manually defining regions of
interest in the tissue that represented tumor, stroma, fat (adipocytes), and then training the software to
recognize these regions of interest. Disease score was expressed as a percentage of the whole tissue
area that contained tumor and/or stroma (Figure 1A).
Immunofluorescence
Gels were fixed overnight in 10% neutral buffered formalin, washed in PBS and permeabilized in Triton X-
100 (0.5% in PBS) for 10min. Gels were incubated in blocking solution (5% BSA or goat serum), and then
incubated with primary antibody overnight at 4oC. Gels were washed and incubated with fluorescent sec-
ondary antibody, for 1hr protected from light and then washed. Finally, gels were incubated with 0.4 mg/ml
DAPI and then washed. Fluorescent images of tri-cultures were captured on an inverted Zeiss LSM 510
laser-scanning confocal microscope using a 10x or 20x air objective. Specimen images were acquired
with a field of view equal to 238.1 x 238.1mm containing 1024x1024 pixels. All imaging conditions including
laser settings and scan settings were kept constant for all gel groups for each fluorescent-labeled antibody.
Images of monolayers were captured using an EVOS FLoid Cell Imaging Station. For F-actin, Alexa Fluor
568 Phalloidin (A12380, Thermo Fisher Scientific) was used.
Antibodies
The following antibodies were used for immunostaining: anti-actin, a-smooth muscle (clone 1A4, A2547),
anti-VCAN (polyclonal, HPA004726), anti-COL11A1 (polyclonal, HPA052246), anti-COL1A1 (polyclonal,
HPA011795), anti-FN1 (polyclonal, F3648) all from Sigma-Aldrich, UK; anti-Ki67 (cloneMIB-1, M7240),
from Dako, UK; anti-fibroblast activation protein, alpha (EPR 20021, ab207178), anti-COMP (ab11056),
anti-CTSB (CA10, ab58802), anti-TGFb all from Abcam; anti-PAX8 (NBP1-32440) from Novus; anti-EPCAM
Alexa Fluor 488 conjugated (53-8326-41) from Thermo-Fisher; GLI-1 Antibody (C-1, sc-515751) from Santa
Cruz Biotechnology.
ICGC analysis for six matrisome molecules
The ICGC_OV read counts across 93 primary tumors were extracted from the exp_seq.OV-AU.tsv.gz file in
the ICGC data repository Release 20 (http://dcc.icgc.org). Only genes that achieved at least one read count
in at least ten samples were selected, producing 18,010 filtered genes in total. Variance stabilizing trans-
formation was then applied using the rlog function (Love et al., 2014). Overall survival (OS) was extracted
from the donor.OV-AU.tsv.gz file. Mean expression for the six matrisome genes was calculated for each
sample and high and low matrix groups were determined using the method described previously (Mihaly
et al., 2013). Survival modeling and Kaplan-Meier (KM) analysis was undertaken using R package survival.
OS was defined as time from diagnosis to death, or to the last follow-up date for survivors. The significantly
differentially expressed genes were selected using a false discovery rate (FDR) < 0.05.
RNA-seq and analysis
RNA-seq was performed by the Wellcome Trust Centre for Human Genetics (Oxford, UK) to approximately
30x mean depth for the HGSOC cell lines or 20x for the 3D cultures. The sequencing was carried out on the
Illumina HiSeq4000 or on the NovaSeq6000 platform, strand-specific, generating 150bp paired-end reads.
RNA-Seq reads were mapped to the human genome (hg19, Genome Reference Consortium GRCh37) in
strand-specific mode as part of theWellcome Trust Centre pipeline. Number of reads aligned to the exonic
region of each gene were counted using htseq-count based on the Ensembl annotation (Anders et al.,
2014). Only genes that achieved at least one read count per million reads (cpm) in at least twenty-five
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percent of the samples were kept. Conditional quantile normalization was performed counting for gene
length and GC content and a log2 transformed RPKM expression matrix was generated. RNA-Seq data
have been deposited in Gene Expression Omnibus (GEO) under the accession number GSE125109.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses and graphics were performed in GraphPad Prism or the programming language R
(version 3.1.3). All correlations were calculated using Spearman’s rank correlation. For pairwise compari-
sons a two-way paired t-test was used. For comparisons of >t2 sample means, one-way ANOVA with Tu-
key’s HSD test were used. Differential expression analysis was performed in Edge R using limma (Ritchie
et al., 2015; Subramanian et al., 2005).Gene-set enrichment analysis (GSEA) was performed using the
GSEA software (Mootha et al., 2003) to identify the canonical pathways gene sets from the Molecular Sig-
natures Database (MSigDB-C2-CP v6.2). See figure legends for significance levels and number of samples,
n. For experiments involving OFs, n represents technical replicates and N represents number of donors.
Data were considered statistically significant from p < 0.05.
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